StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Elite Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.10M, down 18.4% year over year. For fiscal 2026 it was $5.74M, down 27.9% from the year before. Over ten years it grew -7.4% a year on average. The highest annual figure on record is $14.73M in fiscal 2015.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$5.74M-27.9%
FY2025Mar 31, 2025$7.96M+15.7%
FY2024Mar 31, 2024$6.88M+11.0%
FY2023Mar 31, 2023$6.20M+53.0%
FY2022Mar 31, 2022$4.05M-20.8%
FY2021Mar 31, 2021$5.11M-7.6%
FY2020Mar 31, 2020$5.53M-27.2%
FY2019Mar 31, 2019$7.60M-21.0%
FY2018Mar 31, 2018$9.62M+15.9%
FY2017Mar 31, 2017$8.30M-33.2%
FY2016Mar 31, 2016$12.43M-15.6%
FY2015Mar 31, 2015$14.73M+272.0%
FY2014Mar 31, 2014$3.96M+306.0%
FY2013Mar 31, 2013$975.25K-43.8%
FY2012Mar 31, 2012$1.74M+25.3%
FY2011Mar 31, 2011$1.39M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$2.03M+21.3%
Q4 FY2026CQ1 2026Mar 31, 2026$1.64M-19.6%
Q3 FY2026CQ4 2025Dec 31, 2025$1.04M-42.0%
Q2 FY2026CQ3 2025Sep 30, 2025$1.39M-29.5%
Q1 FY2026CQ2 2025Jun 30, 2025$1.67M-22.6%
Q4 FY2025CQ1 2025Mar 31, 2025$2.04M+18.8%
Q3 FY2025CQ4 2024Dec 31, 2024$1.79M+27.8%
Q2 FY2025CQ3 2024Sep 30, 2024$1.97M-24.9%
Q1 FY2025CQ2 2024Jun 30, 2024$2.16M+89.2%
Q4 FY2024CQ1 2024Mar 31, 2024$1.72M-29.2%
Q3 FY2024CQ4 2023Dec 31, 2023$1.40M-2.7%
Q2 FY2024CQ3 2023Sep 30, 2023$2.62M+113.3%
Q1 FY2024CQ2 2023Jun 30, 2023$1.14M+19.7%
Q4 FY2023CQ1 2023Mar 31, 2023$2.43M+228.2%
Q3 FY2023CQ4 2022Dec 31, 2022$1.44M+50.9%
Q2 FY2023CQ3 2022Sep 30, 2022$1.23M+9.9%
Q1 FY2023CQ2 2022Jun 30, 2022$955.44K-20.5%
Q4 FY2022CQ1 2022Mar 31, 2022$738.81K-58.4%
Q3 FY2022CQ4 2021Dec 31, 2021$956.63K-23.2%
Q2 FY2022CQ3 2021Sep 30, 2021$1.12M-2.7%
Q1 FY2022CQ2 2021Jun 30, 2021$1.20M+27.4%
Q4 FY2021CQ1 2021Mar 31, 2021$1.78M-29.0%
Q3 FY2021CQ4 2020Dec 31, 2020$1.25M+26.2%
Q2 FY2021CQ3 2020Sep 30, 2020$1.15M+80.0%
Q1 FY2021CQ2 2020Jun 30, 2020$943.88K-33.0%
Q4 FY2020CQ1 2020Mar 31, 2020$2.50M+83.3%
Q3 FY2020CQ4 2019Dec 31, 2019$986.83K-59.8%
Q2 FY2020CQ3 2019Sep 30, 2019$637.49K-74.0%
Q1 FY2020CQ2 2019Jun 30, 2019$1.41M+6.1%
Q4 FY2019CQ1 2019Mar 31, 2019$1.36M-57.7%
Q3 FY2019CQ4 2018Dec 31, 2018$2.45M+7.2%
Q2 FY2019CQ3 2018Sep 30, 2018$2.46M+7.4%
Q1 FY2019CQ2 2018Jun 30, 2018$1.33M-32.5%
Q4 FY2018CQ1 2018Mar 31, 2018$3.22M-19.2%
Q3 FY2018CQ4 2017Dec 31, 2017$2.29M+50.0%
Q2 FY2018CQ3 2017Sep 30, 2017$2.29M+80.5%
Q1 FY2018CQ2 2017Jun 30, 2017$1.97M–
Q4 FY2017CQ1 2017Mar 31, 2017$3.99M–
Q3 FY2017CQ4 2016Dec 31, 2016$1.53M–
Q2 FY2017CQ3 2016Sep 30, 2016$1.27M–

More Elite Pharmaceuticals figures

See a number that looks wrong?